INTRODUCTION

Statistical analysis
We performed a two-stage association analysis. In the first stage, survival analyses were performed on the basis of the discovery GWAS dataset. In order to reach satisfactory power, we used a significant level of 0.01. We also used the false discovery rate (FDR) to evaluate the proportion of false positives among our findings (37) . The survival time was defined as the length of period (unit: month) from the time of diagnosis until death or the latest follow-up.
Cox proportional hazards model analysis was performed on both early-and late-stage patients. PCs were adjusted in the multivariate Cox model. To remove the possible adverse influence of some long-term survivors and allow for easy comparisons with other similar studies, those late-stage patients with more than 5 years of overall survival were right-censored. The PCs included in the model were generated by the EIGENSTRAT analysis, which were used to control for the confounding effect of population stratification (38, 39) . The significant SNPs observed in stage 1 were then evaluated in two independent cohorts in stage 2 with a significance level of 0.05. Meta-analysis was performed to synthesize the results from different study cohorts. To evaluate the association of the validated miRNA SNPs on NSCLC survival, we performed a time-dependent receiver operating characteristic (ROC) analysis to calculate the cumulative area-under-the-curve(AUC) of the miRNA SNPs, as proposed by Chambless and Diao (40) .
We used PLINK 1.07 for GWAS data management and general statistical analysis (41 "survival" package in R (PLINK plug-in; http://www.r-project.org/ ) was used to conduct the survival analysis. Meta-analysis was performed by using "metan" package in Stata (version 12).
The time-dependent ROC analysis was performed using the "survAUC" package in R. The target mRNAs of the miRNAs, including miR-#-5p and miR-#-3p, were predicted by using TargetScan (42) , and the predicted mRNAs were further queried for GO functional enrichments using CapitalBio Molecule Annotation System V4.0 (MAS, http://bioinfo.capitalbio.com/mas3/).
RESULTS
Characteristics of the NSCLC cases in the discovery set and the two replication patient cohorts are described in Tables 2 and 3, as well as Table 1S , Figures 1S and 2S in the supplementary material.
To validate these findings, we analyzed miRNA SNPs with P <0.01 from the discovery set in the two replication populations. Of the seven SNPs, rs7522956 and rs2042253 were found in the M.D. Anderson cohort's imputed dataset. Only rs2042253, was significant at the level of 0.05 with the effect in the same direction as the discovery set (HR=0.86, 95%CI: 0.74~0.99, P =0.035). And only rs2042253 was identified in the imputed dataset from the Nanjing cohort but was not significantly associated with survival (Table 2S in the supplementary material). We then performed a meta-analysis on rs7522956 and rs2042253, which existed in the datasets of at least two of the three cohorts. The results are presented by Table 4 . None of the effects of the two SNPs were significantly heterogeneous among the cohorts (rs7522956: P =0.106; rs2042253: P =0.757). Thus we used fixed effects model for data synthesis. In the present study, we used genotype data generated from three GWAS datasets to examine the association of miRNA SNPs with the survival of NSCLC patients. In the first stage, by using the Harvard Cohort, we found seven miRNA SNPs to be associated with survival of early- The present study has several strengths. We used three relatively large datasets from three independent GWASs for the discovery and confirmation of the association between miRNA SNPs and overall survival. Thus, SNPs that were identified by the analysis should have a high probability of being true-positive findings. We also performed a time-dependent AUC to In conclusion, the present study provides evidence that SNPs in some miRNAs are associated with NSCLC survival. Our result provides evidence for the application of miRNA SNPs as predictive biomarkers in future personalized medicine for NSCLC patients. Further investigation is needed to illustrate the precise mechanism by which the miRNA SNP's affect NSCLC survival. 
